Significance Statement {#s1}
======================

ASD is a heterogeneous developmental condition that is estimated to affect 1 in 68 children under 8 years of age in the United States. Postmortem studies suggest that both neurons and glia may be compromised in ASD, but few studies have explored neural and glial plasticity across relevant mouse models. We found a decrease in adult neurogenesis in the ventral hippocampus, a brain region important for anxiety and stress regulation, in two autism mouse models compared with wild-type controls. However, we found no differences in markers of glial dysregulation across autism mouse models in the hippocampus, medial prefrontal cortex, or striatum, suggesting that persistent abnormalities in glia in these brain regions are not necessary for the ASD behavioral phenotype.

Introduction {#s2}
============

ASD is characterized by deficits in social communication, repetitive behaviors, and/or restricted interests ([@B2]), and is often associated with cognitive deficits ([@B21]) and increased prevalence of anxiety disorders ([@B58]; [@B49]). Neuroimaging and postmortem studies of ASD individuals have identified an atypical structure in a variety of brain regions, including, but not limited to, the hippocampus, the medial prefrontal cortex (mPFC), and the striatum ([@B52]; [@B10]; [@B30]), regions implicated in the regulation of cognition, anxiety, and stereotyped behavior. Additionally, postmortem studies have revealed greater numbers of dendritic spines ([@B23]; [@B46]), sites of excitatory synapses, when compared with controls, potentially due to abnormal synapse elimination during prenatal and postnatal development.

ASD is a highly heritable disorder with concordance rates as high as 90% between monozygotic twins and 30% between siblings ([@B48]; [@B19]; [@B42]). Furthermore, studies have identified hundreds of genes associated with the disorder, many of which encode for proteins important for synaptic structure and function ([@B19]; [@B43]). Transgenic mice based on rare mutations offer tractable models with which to study the development of ASD, test potential treatments, as well as study changes in cell function and behavior ([@B31]). Knockout of Cntnap2, a gene encoding for a neuronal transmembrane protein that is thought to be important for the control of neuron--glia interactions, is associated with alterations in synaptic structure, neuronal network activity, and an autism-related phenotype in mice ([@B45]; [@B20]). Shank3 mutations are linked to the development of Phelan-McDermid Syndrome (22q13 deletion syndrome), a disorder that presents with many of the core symptoms of ASD as well as global developmental delays ([@B25]). Shank3 encodes for a scaffolding protein that is involved in the maintenance of the postsynaptic density. Mice with partial or complete deletion of Shank3 have deficits in social interaction and cognition as well as alterations in synaptic physiology ([@B25]; [@B28]).

Several lines of evidence point to an important role for glial dysregulation in ASD. Prenatal maternal illness and stress, conditions that stimulate the maternal immune system and induce reactive gliosis ([@B63]), predispose offspring to develop ASD ([@B26]; [@B4]). Not only have postmortem studies shown that individuals with ASD have increased numbers of astrocytes and microglia in a variety of brain regions ([@B57]; [@B36]), but these studies have also revealed abnormalities in peripheral proinflammatory cytokine levels in individuals with ASD ([@B3]; [@B62]). While traditionally thought of as support cells, recent evidence has implicated a role for astrocytes in synapse formation ([@B12]; [@B29]) and elimination ([@B13]), as well as in synaptic plasticity ([@B22]). Microglia, the resident immune cells of the brain, are also known to sculpt neural circuits by engulfing weak synapses during development ([@B44]; [@B50]). Reactive microglia produce several inflammatory molecules that can directly impact synaptic plasticity by altering firing rates and degrading synapses ([@B27]). Since both astrocytes and microglia are involved in shaping and modulating neural connectivity, their early disruption may contribute to abnormal brain development and an ASD phenotype.

In addition to glial plasticity, another form of plasticity, adult neurogenesis in the hippocampus, may also be altered in ASD. Reduced adult neurogenesis in the hippocampus has been reported in the BTBR mouse model of autism ([@B54]); however, no work has explored the possibility that this is a feature common to other ASD mouse models. Because adult neurogenesis has been linked to a variety of hippocampus-mediated behaviors, including learning and memory, anxiety regulation, as well as social behaviors ([@B40]; [@B41]), it is possible that alterations in adult neurogenesis may underlie part of the abnormal behavioral phenotype seen in autism.

To explore the possibility that genetic mouse models of ASD are associated with differences in neuronal and glial plasticity, we examined the number of new neurons and radial glia in the hippocampus, as well as the number, morphology, and reactivity of astrocytes and microglia in the hippocampus, mPFC, and striatum of Cntnap2^−/−^, Shank3^+/ΔC^, and wild-type (WT) male mice.

Materials and Methods {#s3}
=====================

Animals {#s3A}
-------

All animal procedures were performed in accordance with the Princeton University Institutional Animal Care and Use Committee regulations and conformed to the National Research Council Guide for the Care and Use of Laboratory Animals (2011). Adult male C57BL/6J (catalog \#000664) and Cntnap2^−/−^ (catalog \#017482) mice were obtained from The Jackson Laboratory. Shank3^+/ΔC^ (catalog \#018398) mice were originally obtained from The Jackson Laboratory and bred at Princeton University using a heterozygote--heterozygote strategy. For all experiments, 5- to 6-month-old mice were used. Since there is an increased prevalence of ASD among males ([@B11]), only male mice were used for these studies (*n* = 5-10/group). All mice were group housed in Optimice cages on a reverse 12 h light/dark cycle.

Immunohistochemistry {#s3B}
--------------------

Mice were deeply anesthetized with Euthasol and transcardially perfused with 4% paraformaldehyde (PFA) in PBS. Following perfusions, brains were postfixed for 48 h in 4% PFA followed by cryoprotection with sucrose for 48 h. 40-μm-thick coronal sections were cut from half brains using a Cryostat (Leica Biosystems). For immature neuron immunolabeling, free-floating sections throughout the hippocampus were rinsed in Tris-buffered saline (TBS) and then incubated with 0.5% Tween-20, 3% normal donkey serum, and goat anti-doublecortin (DCX; 1:100; Santa Cruz Biotechnology) in TBS at 4°C for 48 h. Sections were then washed and incubated with Alexa Fluor donkey anti-goat 568 (1:250; Invitrogen) for 1 h at room temperature.

Astrocyte and microglial immunolabeling were conducted separately on free-floating sections that were rinsed in PBS, incubated with 3% normal donkey serum, PBS with 0.1% Triton X-100, and rabbit anti-glial fibrillary acidic protein (GFAP; 1:500; Dako), a cytoskeletal astrocyte marker; rabbit anti-S100 (1:10,000, Dako), a Ca^2+^ binding protein that labels astrocyte cell bodies; or rabbit anti-ionized calcium-binding adapter molecule 1 (Iba1; 1:500; Wako), a microglial cell body marker; and rat anti-CD68 (1:200; Serotec), a microglial lysosomal marker. All tissue was incubated in primary antisera for 24 h at 4°C, and then rinsed and incubated with secondary antisera, consisting of either Alexa Fluor donkey anti-rabbit 488 (1:250; Invitrogen) or Alexa Fluor donkey anti-rabbit 568 (1:250; Invitrogen) for astrocyte analyses, or both Alexa Fluor donkey anti-rabbit 488 (1:250; Invitrogen) and Alexa Fluor donkey anti-rat 568 (1:250; Invitrogen) for microglial analyses. Sections were kept in the dark for 1 h, at which point they were rinsed, mounted onto Suprafrost slides, and coverslipped using glycerol in PBS (3:1).

Cell density measurements {#s3C}
-------------------------

Slides were coded until completion of the data analysis. Since the dorsal and ventral regions of the hippocampus are considered functionally distinct ([@B17]), all measures in these regions were analyzed separately (dorsal to bregma, −0.94 to −3.16 mm; ventral to bregma, −3.16 to −3.88 mm; [@B18]). For dorsal hippocampus, mPFC, and striatum, four to six sections were analyzed for cell densities. Since the anterior--posterior extent of the ventral hippocampus is relatively small compared with the dorsal hippocampus, fewer sections were analyzed for this subregion (two to three sections). Because the boundaries of the hippocampus were easy to define, quantitative analyses of cell densities (DCX, GFAP, S100, and Iba1) in this brain region were obtained from counts of the overall structure using Stereo Investigator software (Microbrightfield Bioscience). Briefly, the extent of the individual subregions \[subgranular zone (SGZ), molecular layer (MOL), and stratum radiatum (RAD)\] were outlined, and any positive cells within the delineated region were counted exhaustively. Densities were determined by dividing the total number of positive cells by the volume of the region outlined. Since GFAP^+^ cells in the subgranular zone with radial morphology represent radial-glial-like progenitor cells with stem cell properties ([@B33]), GFAP^+^ cells exhibiting radial and horizontal morphologies were counted separately. Because the precise boundaries of the mPFC (layers 2/3), dorsolateral striatum (DLS), and dorsomedial striatum (DMS) are more difficult to determine, density measurements were made anterior to posterior from the center of each structure following mouse brain atlas coordinates ([@B18]), taking care to avoid the edges, where cells from adjacent structures might be inadvertently included. Cells were counted exhaustively from 20 µm image stacks obtained by use of a Zeiss confocal microscope (LSM 700; lasers: argon 458/488, HeNe 568) followed by processing in ImageJ (NIH). Densities were determined by dividing the total number of positive cells by the volume of the region contained in the stack.

Astroglia analyses {#s3D}
------------------

Astroglia morphology was analyzed using S100 for cell body area and GFAP for cell domain area. Cross-sectional cell body area measurements of 50 S100^+^ cells (10--25 cells per section) were randomly selected per animal per brain region (hippocampus, mPFC, and striatum) from a minimum of two sections per brain region per animal. For GFAP domain area analyses, 50 cells per region per animal (10-25 cells per section for each brain region) were randomly selected from a minimum of two sections per brain region per animal and traced by closely following the contours of the distally stained processes using ImageJ (NIH; [@B39]). The *z*-stack images for S100 and GFAP were obtained using a 20× objective with 2× zoom and a 3 µm *z*-step. Because GFAP^+^ cells in the SGZ are either horizontal or radial-glial-like precursor cells, the GFAP domain area was not examined in this subregion.

Microglial analyses {#s3E}
-------------------

Iba1^+^ microglial cells were analyzed for the number of primary processes, cell body area, and activation status. Cross-sectional cell body area measurements of 10 randomly selected Iba1^+^ cells (two to five cells per section for each brain region) per animal were obtained from 20 µm image *z*-stacks using ImageJ (NIH). The *z*-stack images for Iba1^+^ were obtained with a 63× objective with a 0.7× zoom and a 0.56 µm *z*-step. In order to fully analyze the microglia processes, only Iba1-labeled cells in which the cell body was located toward the middle portion of the *z*-plane were selected for imaging.

Iba1^+^ microglial cells colabeled with lysosomal marker CD68, a marker of microglial activation, were assessed using two methods. The first method involved obtaining area measurements of CD68 staining in Iba1^+^ cells using a confocal microscope and ImageJ software. The second method was adapted from [@B50] and involved manual counting of CD68-stained aggregates within Iba1^+^ microglial cells. For both methods, *z*-stack images were collected for 10 individual Iba1^+^ cells (two to five cells per section) from each brain region per animal using a 63× objective with a 0.7× zoom and a 0.56 µm *z*-step on a Zeiss confocal microscope (LSM 700). Maximum intensity *z*-projections of the image stacks were created using ImageJ (NIH). For the manual counting method, aggregates were counted from the cell body and the processes of each individual microglial cell.

Statistics {#s3F}
----------

Data collection and analyses were performed by an experimenter who was blind to the animal group. For all experiments, data were analyzed by one-way ANOVA with Bonferroni *post hoc* comparisons ([Table 1](#T1){ref-type="table"}), except data sets that violated assumptions of homogeneity of variance or normal distribution (determined by the use of Bartlett's tests). Those datasets were analyzed using Kruskal--Wallis, followed by Dunn's, tests. GraphPad Prism 6.0 (GraphPad Software) was used for all the statistical analyses and graph preparation.

###### 

Statistical table

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Figure    Description                                      Data Structure                      HOV                      Type of test                                    95% CI for WT                                      95% CI for Cntnap2^−/−^                            95% CI for Shank3^+/Δ^
  --------- ------------------------------------------------ ----------------------------------- ------------------------ ----------------------------------------------- -------------------------------------------------- -------------------------------------------------- --------------------------------------------------
  [@B1]B    DCX in the dorsal hippocampus                    Normal                              Yes                      One-way ANOVA                                   14,077--17,780                                     9,654--17,352                                      11,360--18,927

  [@B1]D    DCX in the ventral hippocampus                   Normal                              Yes                      One-way ANOVA                                   9,513--17,496                                      4,572--11,025                                      6,619--9,370

  [@B2]C    rGCs and hGCs in the dorsal hippocampus          Normal                              Yes                      One-way ANOVA                                   8,381--10,624 (rGCs)\                              8,709--10,961 (rGCs)\                              7,668--11,762 (rGCs)\
                                                                                                                                                                          15,576--17,671 (hGCs)                              14,914--16,793 (hGCs)                              15,604--19,204 (hGCs)

  [@B2]F    rGCs and hGCs in the ventral hippocampus         Normal                              Yes                      One-way ANOVA                                   6,766--10,273 (rGCs)\                              3,469--7,123\                                      4,636--6,844\
                                                                                                                                                                          16,066--19,354 (hGCs)                              (rGCs)\                                            (rGCs)\
                                                                                                                                                                                                                             18,018--20,874 (hGCs)                              17,658--21,043 (hGCs)

  N/A       rGCs and DCX cells in the hippocampus            Normal                              Yes                      One-way ANOVA                                   0.51--0.71\                                        0.59--0.89\                                        0.51--0.82\
                                                                                                                                                                          (dorsal)\                                          (dorsal)\                                          (dorsal)\
                                                                                                                                                                          0.47--0.82 (ventral)                               0.57--0.98 (ventral)                               0.49--0.89 (ventral)

  [@B3]B    GFAP density in the dorsal hippocampus           Non-normal (MOL)Normal (RAD)        No (MOL)Yes (RAD)        Kruskal--Wallis (MOLOne-way ANOVA (RAD)         30,863--35,020 (MOL)27,638--32,713 (RAD)           31,880--35,640 (MOL)27,138--31,130 (RAD)           26,868--39,752 (MOL)27,501--32,706 (RAD)

  [@B3]C    GFAP domain area in the dorsal hippocampus       Normal                              Yes                      One-way ANOVA                                   795--1,063 (MOL)912--1,168 (RAD)                   756--935 (MOL)869--1,202 (RAD)                     731--870 (MOL)630--899 (RAD)

  [@B3]E    GFAP density in the ventral hippocampus          Normal                              Yes                      One-way ANOVA                                   33,738--37,726 (MOL)25,884--30,244 (RAD)           36,894--40,994 (MOL)24,924--29,812 (RAD)           30,727--39,249 (MOL)23,393--30,019 (RAD)

  [@B3]F    GFAP domain area in the ventral hippocampus      Normal                              Yes                      One-way ANOVA                                   749--911 (MOL)846--1,154 (RAD)                     669--860 (MOL)825--1,346 (RAD)                     635--860 (MOL)905--1,185 (RAD)

  [@B4]B    S100 density in the dorsal hippocampus           Normal                              Yes                      One-way ANOVA                                   17,245--21,751 (MOL)15,107--18,016 (RAD)           14,940--17,997 (MOL)12,518--15,539 (RAD)           12,911--21,489 (MOL)11,923--18,519 (RAD)

  [@B4]C    S100 morphology in the dorsal hippocampus        Normal                              Yes                      One-way ANOVA                                   51--64 (MOL)48--60 (RAD)                           51--65 (MOL)51--60 (RAD)                           44--63 (MOL)47--63 (RAD)

  [@B4]E    S100 density in the ventral hippocampus          Normal                              Yes                      One-way ANOVA                                   19,035--25,859 (MOL)13,518--17,458 (RAD)           14,146--19,274 (MOL)11,222--13,369 (RAD)           15,336--23,375 (MOL)11,410--16,797 (RAD)

  [@B4]F    S100 morphology in the ventral hippocampus       Normal                              Yes                      One-way ANOVA                                   47--59 (MOL)55--64 (RAD)                           48--61 (MOL)58--64 (RAD)                           42--57 (MOL)53--65 (RAD)

  [@B5]B    Iba1 density in the dorsal hippocampus           Normal                              Yes                      One-way ANOVA                                   8,089--10,437 (MOL)8,091--9,830 (RAD)              8,800--10,325 (MOL)8,378--9,594 (RAD)              8,742--10,086 (MOL)8,160--9,113 (RAD)

  [@B5]C    Iba1 cell body area in the dorsal hippocampus    Normal                              Yes                      One-way ANOVA                                   44--47 (MOL)41--43 (SGZ)41--45 (RAD)               44--47 (MOL)42--44 (SGZ)42--45 (RAD)               43--48 (MOL)41--45 (SGZ)42--46 (RAD)

  N/A       Iba1 processes in the dorsal hippocampus         Normal                              Yes                      One-way ANOVA                                   5.38--6.49 (MOL)4.58--5.40 (SGZ)5.58--7.46 (RAD)   5.96--6.82 (MOL)5.11--5.78 (SGZ)5.05--7.37 (RAD)   5.56--6.50 (MOL)5.16--6.36 (SGZ)6.53--7.87 (RAD)

  [@B5]E    Iba1 density in the ventral hippocampus          Normal                              Yes                      One-way ANOVA                                   8,799--11,297 (MOL)7,208--8,912 (RAD)              7,995--9,825 (MOL)7,500--9,681 (RAD)               8,597--10,955 (MOL)7,279--8,814 (RAD)

  [@B5]F    Iba1 cell body area in the ventral hippocampus   Normal (MOL, SGZ)Non-normal (RAD)   Yes (MOL, SGZ)No (RAD)   One-way ANOVA (MOL, SGZ)Kruskal--Wallis (RAD)   43--45 (MOL)40--46 (SGZ)40--48 (RAD)               43--46 (MOL)39--45 (SGZ)40--46(RAD)                43--46 (MOL)43--47 (SGZ)43--46 (RAD)

  N/A       Iba1 processes in the ventral hippocampus        Normal                              Yes                      One-way ANOVA                                   5.69--7.19 (MOL)4.58--5.78 (SGZ)5.37--6.95 (RAD)   6.68--7.78 (MOL)4.83--5.83 (SGZ)5.34--7.26 (RAD)   5.32--7.05 (MOL)4.62--5.44 (SGZ)5.88--7.66 (RAD)

  [@B6]B    CD68 percent area in the dorsal hippocampus      Normal                              Yes                      One-way ANOVA                                   25--52 (MOL)30--60 (SGZ)44--71 (RAD)               37--64 (MOL)23--51 (SGZ)46--73 (RAD)               36--60 (MOL)29--70 (SGZ)42--76 (RAD)

  [@B6]D    CD68 percent area in the ventral hippocampus     Normal (MOL, SGZ)Non-normal (RAD)   Yes (MOL, SGZ)No (RAD)   One-way ANOVA (MOL, SGZ)Kruskal--Wallis (RAD)   34--57 (MOL)35--65 (SGZ)43--68 (RAD)               33--63 (MOL)30--54 (SGZ)70--75 (RAD)               36--60 (MOL)25--66 (SGZ)48--77 (RAD)

  N/A       CD68 aggregates in the dorsal hippocampus        Normal                              Yes                      One-way ANOVA                                   1.0--1.7 (MOL)2.4--3.3 (SGZ)1.1--1.4 (RAD)         1.4--2.6 (MOL)2.6--3.2 (SGZ)1.1--1.8 (RAD)         1.3--2.4 (MOL)1.6--2.9 (SGZ)1.1--2.1 (RAD)

  N/A       CD68 aggregates in the ventral hippocampus       Normal (MOL, SGZ)Non-normal (RAD)   Yes (MOL, SGZ)No (RAD)   One-way ANOVA (MOL, SGZ)Kruskal--Wallis (RAD)   0.73--1.2 (MOL)2.7--3.9 (SGZ)1.0--1.7 (RAD)        0.89--1.7 (MOL)2.8--3.6 (SGZ)1.2--1.8 (RAD)        0.85--2.1 (MOL)3.5--4.3 (SGZ)1.0--2.1 (RAD)

  [@B7]B    GFAP density in the mPFC                         Normal                              Yes                      One-way ANOVA                                   14,284--19,637                                     15,287--21,324                                     11,541--21,324

  [@B7]C    GFAP domain area in the mPFC                     Normal                              Yes                      One-way ANOVA                                   672--894                                           404--818                                           558--876

  [@B8]B    S100 density in the mPFC                         Normal                              Yes                      One-way ANOVA                                   37,563--42,408                                     34,360--41,972                                     33,026--44,822

  [@B8]C    S100 cell body area in the mPFC                  Normal                              Yes                      One-way ANOVA                                   57--75                                             54--65                                             59--76

  [@B9]B    Iba1 density in the mPFC                         Normal                              Yes                      One-way ANOVA                                   16,458--20,885                                     17,605--19,476                                     14,107--22,088

  [@B9]C    Iba1 cell body area in the mPFC                  Normal                              Yes                      One-way ANOVA                                   49--59                                             52--61                                             53--61

  N/A       Iba1 processes in the mPFC                       Normal                              Yes                      One-way ANOVA                                   4.27--4.97                                         4.55--5.11                                         3.99--5.13

  [@B10]B   CD68 percent area in the mPFC                    Normal                              Yes                      One-way ANOVA                                   31--42                                             28--39                                             31--53

  N/A       CD68 aggregates in the mPFC                      Normal                              Yes                      One-way ANOVA                                   1.9--3.0                                           2.0--3.2                                           1.5--2.6

  [@B11]B   GFAP density in the DLS                          Normal                              Yes                      One-way ANOVA                                   4,576--9,999                                       2,227--10,600                                      3,141--13,608

  [@B11]C   GFAP domain area in the DLS                      Normal                              Yes                      One-way ANOVA                                   894.1--1,167                                       893.7--1,281                                       731.1--1,238

  [@B11]E   GFAP density in the DMS                          Normal                              Yes                      One-way ANOVA                                   5,431--12,016                                      4,384--13,134                                      4,747--15,096

  [@B11]F   GFAP domain area in the DMS                      Normal                              Yes                      One-way ANOVA                                   794.6--1,085                                       791.2--1,137                                       623.3--1,144

  [@B12]B   S100 density in the DLS                          Normal                              Yes                      One-way ANOVA                                   14,376--20,394                                     15,624--24,349                                     8,112--18,553

  [@B12]C   S100 morphology in the DLS                       Normal                              Yes                      One-way ANOVA                                   39.37--46.03                                       41.13--46.35                                       39.71--46.62

  [@B12]E   S100 density in the DMS                          Normal                              Yes                      One-way ANOVA                                   21,978--29,554                                     20,744--29,426                                     12,672--23,759

  [@B12]F   S100 morphology in the DMS                       Normal                              Yes                      One-way ANOVA                                   42.78--50.88                                       40.93--49.1                                        38.35--47.89

  [@B13]B   Iba1 density in the DLS                          Non-normal                          No                       Kruskal--Wallis                                 8,376--13,633                                      8,812--11,570                                      7,593--9,335

  [@B13]C   Iba1 cell body area in the DLS                   Normal                              Yes                      One-way ANOVA                                   47.11--52.55                                       46.7--53.66                                        44.12--49.94

  N/A       Iba1 processes in the DLS                        Normal                              Yes                      One-way ANOVA                                   5.92--7.52                                         5.89--7.23                                         5.80--6.97

                                                                                                                                                                                                                                                                                

  [@B13]E   Iba1 density in the DMS                          Non-normal                          No                       Kruskal--Wallis                                 7,618--13,277                                      8,374--10,970                                      6,749--9,419

  [@B13]F   Iba1 cell body area in the DMS                   Normal                              Yes                      One-way ANOVA                                   48.51--55.59                                       51.05--57.81                                       45.53--51.25

  N/A       Iba1 processes in the DMS                        Normal                              Yes                      One-way ANOVA                                   5.25--5.85                                         5.97--7.45                                         4.75--6.16

  [@B14]B   CD68 percent area in the DLS                     Non-normal                          No                       Kruskal--Wallis                                 62.06-83.87                                        74.36-80.24                                        59.26-84.94

  [@B14]D   CD68 percent area in the DMS                     Non-normal                          No                       Kruskal--Wallis                                 61.11-82.62                                        75.6-79.02                                         52.09-84.29

  N/A       CD68 aggregates in the DLS                       Non-normal                          No                       Kruskal--Wallis                                 2.43-4.67                                          3.21-4.11                                          2.1-3.73

  N/A       CD68 aggregates in the DMS                       Normal                              Yes                      One-way ANOVA                                   1.84-3.32                                          2.14-3.86                                          1.77-2.95
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

hGC, Horizontal glial cell; rGC, radial glial cell.

Results {#s4}
=======

Immature neurons in the hippocampus {#s4A}
-----------------------------------

No differences were detected in the number of DCX^+^ cells in the dorsal dentate gyrus across mouse models (*F*~(2,24)~ = 0.87, *p* = 0.43; [Fig. 1*A*,*B*](#F1){ref-type="fig"}). However, there was a significant difference in the ventral dentate gyrus (*F*~(2,15)~ = 6.18, *p* = 0.01; [Fig. 1*C*,*D*](#F1){ref-type="fig"}). *Post hoc* analyses showed a statistically significant decrease, such that there was a \>40% reduction in the mean densities of immature DCX^+^ neurons in the ventral dentate gyrus in both mouse models of autism compared to wild-type mice (WT vs Cntnap2^−/−^, *p* = 0.02; WT vs Shank3^+/ΔC^, *p* = 0.02).

![Cntnap2^−/−^ and Shank3^+/ΔC^ mice have reduced numbers of immature neurons in the ventral dentate gyrus of the hippocampus. ***A***, ***C***, Representative images of sections immunolabeled with the immature neuronal marker DCX (red) and counterstained with Hoechst 33342 (blue) from WT, Cntnap2^−/−^, and Shank3^+/ΔC^ mice in the dorsal (***A***) and ventral (***C***) dentate gyrus. Scale bar, 20 µm, applies to all frames. Arrows point to DCX^+^ cells. ***B***, ***D***, Quantification of the number of new neurons in the dorsal (***B***) and ventral (***D***) dentate gyrus. Error bars represent the SEM. \**p* \< 0.05.](enu0051621440001){#F1}

Astroglia in the hippocampus {#s4B}
----------------------------

Quantitative analyses of the number of GFAP-stained astrocytes in the dorsal dentate gyrus revealed no significant differences between transgenic and wild-type mice in the SGZ (radial morphology: *F*~(2,23)~ = 0.09, *p* = 0.91; horizontal morphology: *F*~(2,23)~ = 2.03, *p* = 0.15; [Fig. 2*A--C*](#F2){ref-type="fig"}), the MOL of the dentate gyrus (H = 0.98, 2 df, *p* = 0.61; [Fig. 3*A*,*B*](#F3){ref-type="fig"}), or the RAD of the CA1 region (*F*~(2,24)~ = 0.34, *p* = 0.72; [Fig. 3*A*,*B*](#F3){ref-type="fig"}). Within the ventral SGZ, an overall significant effect in the number of GFAP^+^ cells with radial glial morphology, astroglial cells known to serve as progenitors for new neurons in the adult dentate gyrus, was observed (*F*~(2,22)~ = 6.34, *p* = 0.007; [Fig. 2*D*,*F*](#F2){ref-type="fig"}). *Post hoc* analyses showed a significant decrease in density across both transgenic mouse models compared with wild-type controls (WT vs Cntnap2^−/−^, *p* = 0.007; WT vs Shank3^+/ΔC^, *p* = 0.03). By contrast, no difference was observed in this same region in the number of GFAP^+^ cells with horizontal morphology (*F*~(2,22)~ = 2.15, *p* = 0.14; [Fig. 2*E*,*F*](#F2){ref-type="fig"}). Examination of the proportion of the number of radial glia to the number of DCX^+^ cells revealed no differences in either the dorsal SGZ (*F*~(2,23)~ = 1.37, *p* = 0.27) or the ventral SGZ (*F*~(2,13)~ = 0.78, *p* = 0.48). There was an overall statistical significance in the density of GFAP^+^ cells in the ventral MOL (*F*~(2,24)~ = 3.55, *p* = 0.04; [Fig. 3*D*,*E*](#F3){ref-type="fig"}), but *post hoc* analysis showed no differences between groups (WT vs Cntnap2^−/−^, *p* = 0.09; WT vs Shank3^+/ΔC^, *p* \> 0.99). No differences in GFAP^+^ cell density were detected in the ventral RAD (*F*~(2,24)~ = 0.35, *p* = 0.71; [Fig. 3*D*,*E*](#F3){ref-type="fig"}). A significant decrease in the domain size (the maximum extent of the GFAP-stained processes) of individual GFAP^+^ astrocytes was observed in the dorsal RAD (*F*~(2,24)~ = 5.13, *p* = 0.01) in Shank3^+/ΔC^ mice compared with wild-type mice (*p* = 0.02), but this effect was not observed in Cntnap2^−/−^ mice (*p* \> 0.99), which were virtually identical to wild-type mice on this measure. Moreover, the decrease in GFAP^+^ astrocyte domain size was not observed in the dorsal MOL (*F*~(2,24)~ = 1.79, *p* = 0.19; [Fig. 3*C*](#F3){ref-type="fig"}) or in any of the subregions examined in the ventral hippocampus (MOL: *F*~(2,24)~ = 1.12, *p* = 0.34; RAD: *F*~(2,24)~ = 0.25, *p* = 0.78; [Fig. 3*F*](#F1){ref-type="fig"}).

![Cntnap2^−/−^ and Shank3^+/ΔC^ mice have reduced numbers of GFAP-labeled radial glial progenitor cells in the ventral dentate gyrus of the hippocampus ***A***, ***D***, Representative images of radial glial cells (rGCs) immunolabeled with astrocyte marker GFAP (green) and counterstained with Hoechst 33342 (blue) from the dorsal (***A***) and ventral (***D***) SGZ. Arrows point to GFAP^+^ radial glial cells. Scale bar, 10 µm, applies to all frames. ***B***, ***E***, Representative images of horizontal glial cells (hGCs) from the dorsal (***B***) and ventral (***E***) SGZ. Scale bar, 10 µm, applies to all frames. ***C***, ***F***, Quantification of the density of GFAP-labeled cells with radial glial morphology and horizontal morphology in the dorsal (***C***) and ventral (***F***) SGZ. Error bars represent the SEM. \**p* \< 0.05.](enu0051621440002){#F2}

![No consistent differences were observed in GFAP-labeled astrocyte density or domain size across mouse autism models in the hippocampus. ***A***, ***D***, Representative images of sections immunolabeled with astrocyte marker GFAP (green) from WT, Cntnap2^−/−^, and Shank3^+/ΔC^ mice in the dorsal (***A***) and ventral (***D***) MOL of the dentate gyrus. Scale bar, 20 µm, applies to all frames. ***B***, ***E***, Quantification of the density of GFAP-labeled astrocytes in the dorsal (***B***) and ventral (***E***) hippocampus. ***C***, ***F***, Quantification of GFAP cell domain area in the dorsal (***C***) and ventral (***F***) hippocampus. Error bars represent the SEM. \**p* \< 0.05.](enu0051621440003){#F3}

Examination of the astrocyte marker S100 revealed a slightly different pattern of staining. In the dorsal hippocampus, no significant differences were observed in S100^+^ cell density or cell body area between transgenic and wild-type mice in the MOL (density: *F*~(2,24)~ = 2.27, *p* = 0.13; cell body area: *F*~(2,24)~ = 0.39, *p* = 0.68) or in the RAD (density: *F*~(2,24)~ = 2.51, *p* = 0.10; cell body area: *F*~(2,24)~ = 0.11, *p* = 0.89; [Fig. 4*A--C*](#F4){ref-type="fig"}). In the ventral hippocampal subregions, an overall significant difference in S100^+^ cell density was noted (MOL: *F*~(2,24)~ = 4.56, *p* = 0.02; RAD: *F*~(2,24)~ = 4.41, *p* = 0.02). *Post hoc* analyses revealed a significant decrease in the density of S100^+^ cells in both the MOL and RAD of Cntnap2^−/−^ mice compared with wild-type mice (MOL, *p* = 0.01; RAD, *p* = 0.01). However, no statistical difference was observed on this measure in the Shank3^+/ΔC^ mice (MOL, *p* = 0.31; RAD, *p* = 0.51; [Fig. 4*D*,*E*](#F4){ref-type="fig"}). Furthermore, no statistical differences were observed in cell body area measurements in either the MOL (*F*~(2,24)~ = 0.92, *p* = 0.41) or RAD (*F*~(2,24)~ = 0.36, *p* = 0.70) of the ventral hippocampus ([Fig. 4*F*](#F1){ref-type="fig"}).

![No consistent differences were observed in S100-labeled astrocyte density or cell body size across mouse autism models in the hippocampus. ***A***, ***D***, Representative images of sections immunolabeled with astrocyte marker S100 (green) from WT, Cntnap2^−/−^, and Shank3^+/ΔC^ mice in the dorsal (***A***) and ventral (***D***) MOL of the dentate gyrus. Scale bar, 20 µm, applies to all frames. ***B***, ***E***, Quantification of the density of S100-labeled astrocytes in the dorsal (***B***) and ventral (***E***) hippocampus. ***C***, ***F***, Quantification of S100 cell body area in the dorsal (***C***) and ventral (***F***) hippocampus. Error bars represent the SEM. \**p* \< 0.05.](enu0051621440004){#F4}

Microglia in the hippocampus {#s4C}
----------------------------

Quantitative analyses of the number of Iba1^+^ microglial cells revealed no overall statistical differences in either the dorsal (MOL: *F*~(2,24)~ = 0.14, *p* = 0.87; RAD: *F*~(2,24)~ = 0.33, *p* = 0.72; [Fig. 5*A*,*B*](#F5){ref-type="fig"}) or the ventral (MOL: *F*~(2,24)~ = 1.60, *p* = 0.22; RAD: *F*~(2,24)~ = 0.57, *p* = 0.57; [Fig. 5*D*,*E*](#F5){ref-type="fig"}) hippocampus of transgenic mice compared with wild-type mice. Likewise, there was no consistent difference between groups in microglial cell body area (dorsal: MOL: *F*~(2,24)~ = 0.06, *p* = 0.94; SGZ: *F*~(2,24)~ = 0.69, *p* = 0.51; RAD: *F*~(2,24)~ = 0.39, *p* = 0.68; ventral: MOL: *F*~(2,24)~ = 0.26, *p* = 0.78; SGZ: *F*~(2,24)~ = 1.74, *p* = 0.20; RAD: H = 0.40, 2 df, *p* = 0.82; [Fig. 5*C*,*F*](#F5){ref-type="fig"}) or the number of primary processes (dorsal: MOL: *F*~(2,24)~ = 1.35, *p* = 0.28; RAD: *F*~(2,24)~ = 1.16, *p* = 0.33; ventral: MOL: *F*~(2,24)~ = 3.13, *p* = 0.06; SGZ: *F*~(2,24)~ = 0.11, *p* = 0.90; RAD: *F*~(2,24)~ = 0.60, *p* = 0.56). While there was an overall significant difference in the number of primary processes of microglia in the dorsal SGZ (*F*~(2,24)~ = 4.12, *p* = 0.03), *post hoc* analyses showed that this effect was only in Shank3^+/ΔC^ mice compared with wild-type mice (WT vs Cntnap2^−/−^, *p* = 0.17; WT vs Shank3^+/ΔC^, *p* = 0.02).

![No differences were detected in Iba1-labeled microglia density and cell body size across mouse autism models in the hippocampus. ***A***, ***D***, Representative images of sections immunolabeled with microglia marker Iba1 (green) from WT, Cntnap2^−/−^, and Shank3^+/ΔC^ mice in the dorsal (***A***) and ventral (***D***) MOL of the dentate gyrus. Scale bar, 20 µm, applies to all frames. ***B***, ***E***, Quantification of the density of Iba1-labeled microglia in the dorsal (***B***) and ventral (***E***) hippocampus. ***C***, ***F***, Quantification of Iba1 cell body area in the dorsal (***C***) and ventral (***F***) hippocampus. Error bars represent the SEM.](enu0051621440005){#F5}

Analysis of CD68 immunolabeling, an indicator of microglial reactivity, within Iba1^+^ microglia also yielded no statistically significant differences in the percentage of the labeled area among groups for the dorsal hippocampus (MOL: *F*~(2,24)~ = 1.36, *p* = 0.28; SGZ: *F*~(2,24)~ = 0.82, *p* = 0.45; RAD: *F*~(2,24)~ = 0.03, *p* = 0.98; [Fig. 6*A*,*B*](#F6){ref-type="fig"}) and the ventral hippocampus (MOL: *F*~(2,24)~ = 0.07, *p* = 0.93; SGZ: *F*~(2,24)~ = 0.39, *p* = 0.68; RAD: H = 4.58, 2 df, *p* = 0.10; [Fig. 6*C*,*D*](#F6){ref-type="fig"}). Furthermore, we found no difference in the number of CD68 aggregates in microglia in either the dorsal (MOL: *F*~(2,24)~ = 2.37, *p* = 0.12; SGZ: *F*~(2,24)~ = 2.78, *p* = 0.08; RAD: *F*~(2,24)~ = 0.52, *p* = 0.60) or ventral (MOL: *F*~(2,24)~ = 1.91, *p* = 0.17; SGZ: *F*~(2,24)~ = 2.62, *p* = 0.09; RAD: H = 2.40, 2 df, *p* = 0.30) hippocampus.

![No differences were detected in the percentage area of CD68 in Iba1^+^ cells across mouse autism models in the hippocampus. ***A***, ***C***, Representative images of sections double labeled with microglia marker Iba1 (green) and microglial lysosomal marker CD68 (red) from WT, Cntnap2^−/−^, and Shank3^+/ΔC^ mice in the dorsal (***A***) and ventral (***C***) MOL of the dentate gyrus. Arrows point to CD68 aggregate labeling. Scale bar, 10 µm, applies to all frames. ***B***, ***D***, Quantification of the percentage area of CD68 in Iba1-labeled microglia cells in the dorsal (***B***) and ventral (***D***) hippocampus. Error bars represent the SEM.](enu0051621440006){#F6}

Astroglia in the medial prefrontal cortex {#s4D}
-----------------------------------------

No significant differences were observed in GFAP^+^ cell density (*F*~(2,24)~ = 0.31, *p* = 0.74) or domain area (*F*~(2,24)~ = 1.56, *p* = 0.23) in the mPFC when comparing across genotype ([Fig. 7](#F7){ref-type="fig"}). Similar to what was observed for GFAP-labeled tissue in the mPFC, quantitative analyses of S100^+^ density (*F*~(2,24)~ = 0.21, *p* = 0.81) and cell body area (*F*~(2,24)~ =1.61, *p* = 0.22) in the mPFC revealed no significant differences across genotypes ([Fig. 8](#F8){ref-type="fig"}).

![No differences in GFAP-labeled astrocyte density or domain size were detected in the mPFC. ***A***, Representative images of sections immunolabeled with GFAP (green) in the mPFC. Scale bar, 20 µm, applies to all frames. ***B***, Quantitative analysis of GFAP density in the mPFC. ***C***, Quantitative analysis of GFAP domain area in the mPFC. Error bars represent the SEM.](enu0051621440007){#F7}

![No differences in astrocyte number or cell body size were detected in the mPFC using the astrocytic marker S100. ***A***, Representative images of sections immunolabeled with S100 (green) in the mPFC. Scale bar, 20 µm, applies to all frames. ***B***, Quantitative analysis of S100 density in the mPFC. ***C***, Quantitative analysis of S100 cell body area in the mPFC. Error bars represent the SEM.](enu0051621440008){#F8}

Microglia in the medial prefrontal cortex {#s4E}
-----------------------------------------

No significant differences in the density of Iba1^+^ microglia (*F*~(2,24)~ = 0.08, *p* = 0.92) and the cell body area of Iba1^+^ microglia (*F*~(2,24)~ =.64, *p* = 0.54) were observed across genotypes ([Fig. 9](#F9){ref-type="fig"}). Likewise, no differences in the number of primary processes of Iba1^+^ microglia were detected across genotypes (*F*~(2,24)~ = 0.76, *p* = 0.48).

![No differences in Iba1-labeled microglia density or cell body size were detected in the mPFC across groups. ***A***, Representative images of sections immunolabeled with Iba1 (green) in the mPFC. Scale bar, 20 µm, applies to all frames. ***B***, Quantitative analysis of Iba1 density in the mPFC. ***C***, Quantitative analysis of Iba1 cell body area in the mPFC. Error bars represent the SEM.](enu0051621440009){#F9}

No differences were observed in microglial activation, as measured by the percentage of the area of CD68 in Iba1^+^ cells (*F*~(2,24)~ = 1.93, *p* = 0.17; [Fig. 10](#F10){ref-type="fig"}) as well as by counting the number of CD68 aggregates in Iba1^+^ cells (*F*~(2,24)~ = 1.00, *p* = 0.38) across genotypes.

![No differences were detected in the percentage area of CD68 in Iba1^+^ cells across mouse autism models in the mPFC. ***A***, Representative images of sections double labeled with microglia marker Iba1 (green) and microglial lysosomal marker CD68 (red) from WT, Cntnap2^−/−^, and Shank3^+/ΔC^ mice in the mPFC. Scale bar, 10 µm, applies to all frames. Arrows point to CD68 aggregate labeling. ***B***, Quantification of the percentage area of CD68 in Iba1-labeled microglia cells in the mPFC. Error bars represent the SEM.](enu0051621440010){#F10}

Astroglia in the striatum {#s4F}
-------------------------

No significant differences were observed in the number of GFAP^+^ astrocytes between transgenic and wild-type mice in either the DLS (*F*~(2,24)~ = 0.39, *p* = 0.68; [Fig. 11*A*,*B*](#F11){ref-type="fig"}) or in the DMS (*F*~(2,24)~ = 0.27, *p* = 0.77; [Fig. 11*D*,*E*](#F11){ref-type="fig"}). Furthermore, no differences in the domain sizes of individual GFAP^+^ astrocytes were detected in the DLS (*F*~(2,24)~ = 0.38, *p* = 0.69; [Fig. 11*C*](#F11){ref-type="fig"}) or in the DMS (*F*~(2,24)~ = 0.24, *p* = 0.79; [Fig. 11*F*](#F1){ref-type="fig"}).

![No differences were observed in GFAP-labeled astrocyte number and domain size across mouse autism models in the dorsal striatum. ***A***, ***D***, Representative images of sections immunolabeled with GFAP (green) from WT, Cntnap2^−/−^, and Shank3^+/ΔC^ mice in the DLS (***A***) and DMS (***D***). Scale bar, 20 µm, applies to all frames. ***B***, ***E***, Quantification of the density of GFAP-labeled astrocytes in the DLS (***B***) and DMS (***E***). ***C***, ***F***, Quantification of cell domain area of GFAP-labeled astrocytes in the DLS (***C***) and DMS (***F***). Error bars represent the SEM.](enu0051621440011){#F11}

Similar to the analysis of GFAP^+^ astrocytes in the striatum, S100^+^ astrocytes showed no consistent differences between transgenic and wild-type mice in either the DLS (*F*~(2,24)~ = 3.20, *p* = 0.06; [Fig. 12*A*,*B*](#F12){ref-type="fig"}) or in the DMS (*F*~(2,24)~ = 4.1, *p* = 0.03; [Fig. 12*D*,*E*](#F12){ref-type="fig"}). Although an overall significant effect was observed for S100^+^ density in the DMS, *post hoc* comparisons revealed a significant decrease only in Shank3^+/ΔC^ mice compared with wild-type mice (WT vs Shank3^+/ΔC^, *p* = 0.03). This effect was not seen in Cntnap2^−/−^ mice (WT vs Cntnap2^−/−^, *p* \> 0.99). Furthermore, no differences in S100^+^ cell body area were detected in the DLS (*F*~(2,24)~ = 0.16, *p* = 0.85; [Fig. 12*C*](#F12){ref-type="fig"}) or in the DMS (*F*~(2,24)~ = 0.93, *p* = 0.41; [Fig. 12*F*](#F1){ref-type="fig"}).

![No consistent differences were observed in S100-labeled astrocyte number and cell body size across mouse autism models in the dorsal striatum. ***A***, ***D***, Representative images of sections immunolabeled with S100 (green) from WT, Cntnap2^−/−^, and Shank3^+/ΔC^ mice in the DLS (***A***) and DMS (***D***). Scale bar, 20 µm, applies to all frames. ***B***, ***E***, Quantification of the density of S100-labeled astrocytes in the DLS (***B***) and DMS (***E***). ***C***, ***F***, Quantification of cell body area of S100-labeled astrocytes in the DLS (***C***) and DMS (***F***). Error bars represent the SEM. \**p* \< 0.05.](enu0051621440012){#F12}

Microglia in the striatum {#s4G}
-------------------------

There were no differences in the density of Iba1^+^ microglia among the two transgenic models and wild-type mice in either the DLS (H = 4.66, 2 df, *p* = 0.098; [Fig. 13*A*,*B*](#F13){ref-type="fig"}) or the DMS (H = 3.16, 2 df, *p* = 0.21; [Fig. 13*D*,*E*](#F13){ref-type="fig"}). Likewise, there was no overall statistical difference in microglial cell body area among transgenic models and wild-type mice in the DLS (*F*~(2,24)~ = 1.38, *p* = 0.27; [Fig. 13*C*](#F13){ref-type="fig"}). Although an overall significant effect was observed for Iba1^+^ cell body area in the DMS (*F*~(2,24)~ = 3.76, *p* = 0.04; [Fig. 13*F*](#F1){ref-type="fig"}), *post hoc* analysis revealed no significant differences between transgenic and wild-type mice (WT vs Shank3^+/ΔC^, *p* = 0.22; WT vs Cntnap2^−/−^, *p* = 0.49). No significant difference in the number of primary processes of Iba1^+^ microglia was detected in the DLS across genotype (*F*~(2,24)~ = 0.26, *p* = 0.77). Although an overall significant effect for the number of primary processes of Iba1^+^ microglia was observed in the DMS (*F*~(2,24)~ = 7.42, *p* = 0.0031), *post hoc* analysis revealed a significant decrease only in Cntnap2^−/−^ mice compared with wild-type mice (WT vs Cntnap2^−/−^, *p* = 0.0058). This effect was not seen in Shank3^+/ΔC^ mice (WT vs Shank3^+/ΔC^, *p* \> 0.99).

![No consistent differences were observed in Iba1-labeled microglia number and cell body size across mouse models in the dorsal striatum. ***A***, ***D***, Representative images of sections immunolabeled with Iba1 (green) from WT, Cntnap2^−/−^, and Shank3^+/ΔC^ mice in the DLS (***A***) and DMS (***D***). Scale bar, 20 µm, applies to all frames. ***B***, ***E***, Quantification of the density of Iba1-labeled microglia in the DLS (***B***) and DMS (***E***). ***C***, ***F***, Quantification of the cell body area of Iba1-labeled microglia in the DLS (***C***) and DMS (***F***). Error bars represent the SEM.](enu0051621440013){#F13}

Iba1^+^ microglial cells were also analyzed for microglial activation through colabeling with CD68. Quantitative analysis of CD68^+^ percent area revealed no significant effect in the DLS (H = 0.32, 2 df, *p* = 0.85; [Fig. 14*A*,*B*](#F14){ref-type="fig"}). Similarly, no significant difference in microglial activation was seen in the DMS (H = 0.75, 2 df, *p* = 0.69; [Fig. 14*C*,*D*](#F14){ref-type="fig"}). Additionally, the number of CD68 aggregates in Iba1^+^ cells revealed no significant differences across genotype in either the DLS (H = 1.88, 2 df, *p* = 0.39) or the DMS (*F*~(2,24)~ = 0.89, *p* = 0.42).

![No differences were detected in the percentage area of CD68 in Iba1^+^ cells across mouse autism models in the dorsal striatum. ***A***, ***C***, Representative images of sections immunolabeled with Iba1 (green) and microglial lysosomal marker CD68 (red) from WT, Cntnap2^−/−^, and Shank3^+/ΔC^ mice in the DLS (***A***) and DMS (***C***). Arrows point to CD68 aggregate labeling. Scale bar, 10 µm, applies to all frames. ***B***, ***D***, Quantification of the percentage area of CD68 in Iba1-labeled microglia cells in DLS (***B***) and DMS (***D***). Error bars represent the SEM.](enu0051621440014){#F14}

Differences in astroglia across brain regions {#s4H}
---------------------------------------------

In our study, no consistent glial differences were found between wild-type and autism mouse models within the hippocampus, mPFC, or striatum other than in specialized astroglia in the SGZ known to serve as progenitor cells for immature neurons. Microscopic analyses of GFAP^+^ cells with astrocyte morphology revealed different profiles among the hippocampus, mPFC, and striatum ([Figs. 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}, [7](#F7){ref-type="fig"}, [11](#F11){ref-type="fig"}). The density of GFAP-labeled cells (per cubic millimeter) in the dentate gyrus molecular layer and CA1 stratum radiatum of the hippocampus far exceeded that of both the mPFC and striatum. Furthermore, GFAP-labeled astrocytes in the mPFC were on average smaller in domain area compared with the hippocampus and striatum. The overall shape of the GFAP-labeled cells differed; astrocytes in the mPFC appeared to be more spherical in shape with more elaborate branched processes than those in the hippocampus (compare [Figs. 3](#F3){ref-type="fig"}, [7](#F7){ref-type="fig"}). Similar differences in appearance were seen between the striatum and hippocampus, where astrocytes in the striatum appeared to have more branched processes in a spherical pattern, but were similar in domain area (compare [Figs. 3](#F3){ref-type="fig"}, [11](#F11){ref-type="fig"}). Analyses from S100^+^ cells also revealed regional differences in cell density and size. The density of S100^+^ cells (per cubic millimeter) in the mPFC was approximately twice that of the DLS and dentate gyrus molecular layer and CA1 stratum radiatum of the hippocampus. Additionally, the average DLS cell body area of S100^+^ cells was smaller than all other regions (compare [Figs. 4](#F4){ref-type="fig"}, [8](#F8){ref-type="fig"}, [12](#F12){ref-type="fig"}).

Discussion {#s5}
==========

We searched for similar differences in markers of neuronal and glial plasticity in three brain regions in two genetic models of autism compared with wild-type controls. Of the measures we made, the only ones that exhibited similar differences across both ASD mouse models were those related to adult neurogenesis in the hippocampus, namely, the number of doublecortin-labeled cells and the number of radial glial-like progenitor cells. We observed no consistent changes in any other markers of glial plasticity, including the number or size of astrocytes in the hippocampus, mPFC, or striatum, and no differences in the number, size, or activation of microglia in the aforementioned brain regions across both genotypes. Despite not finding consistent differences in markers of astrocytes or microglia across genotypes, differences between genotypes unique to particular cell types were detected in both the hippocampus and striatum. In the hippocampus, GFAP^+^ cell domain areas were smaller in the dorsal stratum radiatum of Shank3^+/ΔC^ animals relative to wild-type controls. Similarly, fewer S100^+^ cells were found in Cntnap2^−/−^ animals in the dorsal molecular layer and stratum radiatum of the hippocampus. In the dorsomedial striatum, fewer S100^+^ cells were detected in Shank3^+/ΔC^ mice. Collectively, these findings suggest that shared differences in adult neurogenesis exist, but that potential differences in glial plasticity associated with ASD may be more subtle, and not necessarily general findings, in the adult brain.

We found a robust decrease in the number of new neurons, as well as in the number of radial glial-like progenitor cells, in the ventral, but not dorsal, dentate gyrus in both Cntnap2^−/−^ and Shank3^+/ΔC^ transgenic mice. The specificity of this finding to the ventral part of the hippocampus may be functionally relevant as, in the rodent, the ventral hippocampus has been linked to anxiety and stress regulation, whereas the dorsal hippocampus has been linked to spatial navigation learning and memory ([@B17]). Since ASD has high comorbidity with anxiety disorders ([@B53]; [@B56]), reduced numbers of new neurons may contribute to increased anxiety. Recent evidence suggests that, in addition to anxiety regulation, new neurons in the ventral dentate gyrus may mediate some social behaviors ([@B41]). Our adult neurogenesis findings are in line with behavioral data showing that Cntnap2^−/−^ and Shank3^+/ΔC^ transgenic mice display more anxiety-like behaviors and deficits in social behaviors compared to wild-type mice ([@B45]; [@B16]). Additionally, our data are also consistent with another study that showed that the BTBR mouse strain, which exhibits many behavioral deficits associated with ASD, has reduced the numbers of adult-born neurons in the hippocampus ([@B54]). However, this study did not differentiate between the dorsal and ventral portions of the dentate gyrus. To determine whether reduced numbers of immature neurons are a general phenomenon of ASD, future work should explore markers of adult neurogenesis in other mouse models, as well as in postmortem human ASD tissue.

Despite clear differences in the numbers of new neurons and astroglial progenitor cells in the ventral hippocampus, we detected no consistent differences across genotypes when looking at mature astrocytes or microglia in this brain region. These findings may be difficult to interpret given the heterogeneity of ASD. In particular, one problem with interpreting genotypic differences between mouse models of ASD is that the rare mutant variants account for \<1% of all ASD cases ([@B14]). Comparing individuals with these specific abnormalities, similarities reflective of the core symptoms of ASD can be seen; however, differences in severity, seizure prevalence, muscle tone, developmental delay, and other comorbid conditions exist ([@B14]; [@B43]). While mouse models based on rare mutations offer useful models to study the development of ASD, there are often difficulties relating behavioral deficits in rodents to those seen in humans ([@B37]). These difficulties may be due, in part, to the likelihood that ASD is caused by multiple genetic factors, which together comprise an individual's genetic liability ([@B19]). Nevertheless, the fact that many of the ASD candidate genes, including Cntnap2 and Shank3, are associated with both neuronal and glial plasticity as well as with synapse development, at least suggests the possibility of shared underlying mechanisms or biomarkers for many, if not all, forms of ASD ([@B9]; [@B45]; [@B25]).

Postmortem studies show increased levels of glial markers in the brains of patients with ASD ([@B57]; [@B36]), and experimental studies have also linked glial dysregulation to ASD. Methyl-CpG-binding protein-2 (MECP2), a transcription factor that is expressed in neurons and glia, is atypically expressed in ASD and mutated in Rett syndrome, which produces many symptoms similar to those in ASD ([@B6]; [@B35]). The absence of MECP2 in astrocytes impedes normal neuronal growth ([@B6]). On the other hand, re-expression of MECP2 in astrocytes of MECP2-null mice restored these alterations in dendritic morphology and significantly improved Rett syndrome-like behaviors, such as locomotion and anxiety levels ([@B32]). Another study ([@B34]) showed that knockout of MECP2 specifically in microglial cells causes stunted dendritic growth of hippocampal neurons and damages the postsynaptic elements of excitatory synapses by increasing the release of glutamate. Mice lacking Cx3Cr1, a chemokine receptor expressed by microglia that is involved in neuron--microglia cross talk, not only have reduced numbers of new neurons ([@B5]), but they also have an autistic-like behavioral phenotype, including impaired social interaction and increased repetitive behaviors ([@B64]). These transgenic mice also exhibit alterations in neural circuitry commonly associated with ASD, including impaired synaptic pruning, weak synaptic transmission, and decreased long-range functional connectivity ([@B44]; [@B64]).

Although we did not find common abnormalities in astrocytes or microglia across the two autism mouse models, our findings do not exclude the possibility that astrocytic and microglial dysfunction are important in the etiology of ASD. Indeed, abnormalities in these cell types may have existed early in life that had resolved by adulthood. The mechanisms of ASD are known to have their onset in the first year of human postnatal life, and many ASD genes are coexpressed in mid-gestation in the developing human brain ([@B61]). In mice, the mechanisms of neocortical synapse proliferation and elimination are likely to reach a peak in the first 2 months of postnatal life ([@B1]). Our measurements, which were performed on mice at later ages, would tend to emphasize aberrations in plasticity mechanisms that persisted even after this period has ended. In this regard, it is notable that our positive results were found in the dentate gyrus, a structure that undergoes a considerable amount of neurogenesis and other forms of plasticity throughout adult life. One potential mechanism is that proper synapse formation and elimination does not occur in ASD individuals, producing abnormal neural connectivity. CD68, a microglial lysosomal marker associated with the engulfment of synapses, is present in high quantities in the mouse brain early in development compared with adulthood ([@B50]). Since both astrocytes and microglia play a role in shaping neural circuitry by actively engulfing weak synapses during early life ([@B44]; [@B50]; [@B13]), glial dysfunction leading to ASD may occur at an early age. In our study, we examined 5- to 6-month-old male mice. The adult time point was specifically chosen because most reported autism-like behaviors for these transgenic lines were examined in adult mice ([@B45]; [@B16]). Thus, future work is needed to determine whether a more consistent and robust alteration in glial cells occurs in mouse models of ASD at younger ages.

It is also possible that astrocyte and microglia abnormalities exist, but are not detectable using our specific measures. Although Iba1 is a well known marker of microglia and robustly labels all cells of macrophage origin ([@B24]), heterogeneity in astrocytic cell populations is an important consideration. Despite the fact that both GFAP and S100 are common markers for astrocytes, these markers only label a relatively small proportion of astrocytes ([@B9]). In fact, not all astrocytes colabel with GFAP and S100 ([@B9]; [@B7]), suggesting that there are different subpopulations of astrocytes, which may be differentially altered in ASD. Additionally, GFAP does not label the entirety of astrocytic processes and is largely absent from astrocytic end feet ([@B8]), so morphology could be altered in ASD but in regions of the cell that do not label with GFAP. Both microglia and astrocytes are highly dynamic and can change morphologies within a matter of minutes ([@B38]; [@B55]; [@B47]). Our findings leave open the possibility that more subtle changes in morphology may occur in ASD as well as in other brain regions that are not explored here but are implicated in ASD ([@B51]; [@B15]; [@B59]).

Our findings, along with those of a previous study ([@B54]), suggest that diminished adult neurogenesis in the hippocampus may be a feature shared by many ASD mouse models. Our additional finding of reduced numbers of astroglial cells with radial morphology in the ventral SGZ suggest that decreased numbers of immature neurons occur as a result of fewer progenitor cells. Since radial glial cells serve as neuronal progenitors during development as well as in adulthood, it is possible that these findings reflect residual evidence of a neurogenesis deficit that exists during development in multiple brain regions. Indeed, studies suggest that some of the gross structural abnormalities detected in the postmortem ASD brain may arise from aberrant neurogenesis ([@B60]). However, the extent to which deficits in radial glial progenitor cells and neurogenesis contribute to symptoms of ASD remains to be determined.
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=========

Reviewing Editor: Liisa Galea, University of British Columbia. Decisions are customarily a result of the Reviewing Editor and the peer reviewers coming together and discussing their recommendations until a consensus is reached. When revisions are invited, a fact-based synthesis statement explaining their decision and outlining what is needed to prepare a revision will be listed below. The following reviewer(s) agreed to reveal their identity: Jason Snyder. For some manuscripts transferred from JNeurosci, a decision is made to accept the manuscript without peer review and a brief statement to this effect will follow.

This is a well-written, comprehensive paper that reports quantitative assays of neurogenesis and glial cell numbers in PFC, hippocampus and striatum of two mouse models of Autism-spectrum disorders (ASDs), Cntnap2-/- and Shank3+/ΔC transgenic mice. The rationale for the experiments is that postmortem studies suggest that neurogenesis and glial populations are abnormal in ASD, but it is not known whether these defects are present across relevant mouse models. The main results are that both ASD mouse models displayed a decrease in the number of immature neurons and radial glial progenitor cells in the ventral dentate gyrus, but no consistent differences were detected in the number or size of astrocytes or microglia in any other brain regions examined. The latter result suggests that glial abnormalities are not necessary for ASD behavioral phenotypes. The cell quantifications are thorough, particularly with respect to glial populations, and will be useful for other researchers interested in ASDs. In addition, the parallel reductions in neurogenesis and radial glia number in both mouse models suggests that these phenotypes deserve more attention.

1\. The reduction in newborn neurons and radial glia calls out for a more mechanistic analysis of changes in the relative proportion of maturation stages. This is one place where a more \"mechanistic\" analysis could have been incorporated without much extra work. One way to begin to answer this question would be to do an analysis of the phenotype of the DCX-expressing neurons. In this way you could address whether you see proportionally different amounts of Type I, type II or type II DCX-expressing neurons between the different mouse lines?

2\. More detail is requested in the Methods section:

1)stereological quantification. Were cells counted exhaustively or was an estimator used, such as optical fractionator? Were guard zones used to avoid overcounting? The use/nonuse of these methods would probably not affect the conclusions of this study but could affect the overall density values and thus will be relevant to other researchers interested in the cell counts.

2)How were the z-stacks obtained for the cross-sectional measurements? Microscope, objective, imaging parameters.

3)Which portions of CA1, dorsal-medial striatum, mPFC were examined (beyond stating the \"center region\")? (CA1 isn\'t even mentioned in the methods) The entire region rostro-caudally, medio-laterally, dorsoventrally? All neocortical layers? What were the dorsoventral boundaries for the dentate gyrus analyses?

4)For the cell area measurements it must be subregional analyses since only 10-50 cells were analysed - how were these chosen/sampled?

5)Is there functionally significant difference between punctate and aggregate CD68 staining? - perhaps a description of the significance could be included and the reason behind measuring them differently.

3\. CD68 is a microglia-specific lysosome marker relevant to phagocytic activity. The Shaffer paper defines activation by taking into account both CD68 expression and microglia morphology using a 0-5 scale, however in this manuscript only CD68 expression but not morphology of Iba-1 cells are analyzed together. If so this is slightly different from the Shaffer method and should be acknowledged ( and perhaps important to also examined according to the morphology of the processes from Iba-1 expressing cells). It is important to acknowledge that there is more to microglial activation than phagocytosis, and by limiting activation analysis to CD68 expression and ignoring morphology some important information may be lost.

4\. For the punctate and aggregate CD68 staining it appears as though these are just different sized chunks of CD68 protein. Differentially weighting anything larger than 3um, by multiplying it 10x more than staining chunks smaller than 3um seems a bit crude. For example, a CD68 signal that is 3.5um would be multiplied 10x more than a signal that measures only 2.5um across. And then are these differentially weighted counts combined? I assume so. Binning them into quartiles will also lose quantitative information. Why not go back to these images and take the CD68 channel and measure the total area occupied by the CD68 signal? This seems like it would be more accurate and would introduce fewer systematic quantitative biases.

5\. The Results section is quite long and could be condensed without reducing the important information but analysis type could be reconsidered- for example instead of conducting two one-way ANOVAs separately for each area of investigation ( e.g. dorsal versus ventral) you could condense these two analyses into one repeated measures ANOVA with dorsal/ventral as your within factor. The same is true of the analyses of the stratum radiatum versus molecular layer ( instead of 2 one-way ANOVAs, 1 RM ANOVA could be conducted). However the effects seen are quite large and thus likely your outcome will not be affected and we leave it up to the authors whether or not they wish to include area as a within-subjects factor in their analyses.

6\. Table 1 is very much appreciated. In addition to normality ANOVA is sensitive to large variations in variance, thus it would be better to have HOV information in addition to normality within this Table ( or a statement indicating both assumptions are tenable for each analysis).

7\. In the introduction, in the second and third sentence, although it is obvious make it clear that these are post-mortem findings in individuals with ASD (only in boys/men?).

8\. Please add \"male\" to the last sentence in Introduction to make it clear this is only in males.

9\. And finally a question for interest may also be whether the relative proportion of new glia and new neurons is altered with each strain? Given evidence that glial populations are affected in ASDs, there may well be differences in adult gliogenesis. Is the mode of division of radial glia altered? Is their rate of division changed? Is neuronal proliferation or survival altered? These are questions that are given as food for thought rather than something that needs to be addressed in the manuscript itself.

[^1]: The authors declare no competing financial interests.

[^2]: Author contributions: E.C.C., B.A.B., A.T.B., S.S.-H.W., and E.G. designed research; E.C.C., B.A.B., A.T.B., S.M., P.-A.V., and M.O. performed research; S.S.-H.W. provided unpublished reagents/analytic tools; E.C.C., B.A.B., A.T.B., S.M., P.-A.V., and M.O. analyzed data; E.C.C., B.A.B., A.T.B., S.S.-H.W., and E.G. wrote the paper.

[^3]: This work was supported by a grant from the Nancy Lurie Marks Family Foundation.

[^4]: B.A.B. and A.T.B. contributed equally to this work.
